MedTrace Logo

Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer

NCT06752408 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 316

Last updated 2024-12-30

No results posted yet for this study

Summary

This is a multicenter, randomized, open-label, non-inferiority real world study. The study is designed to evaluate the efficacy and safety of Aumolertinib versus Osimertinib in the first-line treatment of patients with EGFR mutated locally advanced or metastatic non-small-cell lung cancer.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

Aumolertinib

Aumolertinib will be administered orally at a dose of 110 mg per time, Q.D.

DRUG

Osimertinib

Osimertinib will be administered orally at a dose of 80 mg per time, Q.D.

Sponsors & Collaborators

  • Peking University People's Hospital

    collaborator OTHER

  • China-Japan Friendship Hospital

    collaborator OTHER

  • Peking Union Medical College Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-17
Primary Completion
2027-01-16
Completion
2028-01-16

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06752408 on ClinicalTrials.gov